---
title: "CMPS.US (CMPS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CMPS.US/news.md"
symbol: "CMPS.US"
name: "CMPS.US"
parent: "https://longbridge.com/en/quote/CMPS.US.md"
datetime: "2026-05-21T14:27:56.156Z"
locales:
  - [en](https://longbridge.com/en/quote/CMPS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CMPS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CMPS.US/news.md)
---

# CMPS.US (CMPS.US) — Related News

### [Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins](https://longbridge.com/en/news/287164867.md)
*2026-05-21T06:03:16.000Z*
> Compass Pathways (NASDAQ:CMPS) is on track to file a New Drug Application for its psilocybin treatment, COMP360, targeti

### [This Psychedelics Stock Just Keeps Getting Hotter; Why Shares Bypassed A Profit-Taking Zone](https://longbridge.com/en/news/286791277.md)
*2026-05-18T14:47:32.000Z*
> Compass Pathways experienced a significant surge on Monday due to increasing excitement surrounding the company's use of

### [At a glance: Stocks gapping up premarket](https://longbridge.com/en/news/286762589.md)
*2026-05-18T11:29:18.000Z*
> Stocks are experiencing gap-up moves before the market opens, with LiveRamp Holdings (RAMP) rising 26.7%, Compass Pathwa

### [H.C. Wainwright Sticks to Their Buy Rating for COMPASS Pathways (CMPS)](https://longbridge.com/en/news/286590906.md)
*2026-05-15T15:29:42.000Z*
> H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on COMPASS Pathways (CMPS) with a price target of $70.0

### [COMPASS Pathways - American Depository Shares Stock 12‑Month Price Target Raised to $21.3, Implies 127% Upside](https://longbridge.com/en/news/286306251.md)
*2026-05-13T19:20:05.000Z*
> COMPASS Pathways Plc's American Depository Shares stock price target has been raised to $21.3 from $20.97, indicating a 

### [](https://longbridge.com/en/news/286284558.md)
*2026-05-13T14:50:48.000Z*
> Compass Pathways shares are trading higher after the company reported better-than-expected Q1 EPS results.

### [Compass Pathways Q1 Earnings Call Highlights](https://longbridge.com/en/news/286276544.md)
*2026-05-13T14:07:48.000Z*
> Compass Pathways (NASDAQ:CMPS) has initiated a rolling New Drug Application for its psilocybin treatment, COMP360, aimed

### [COMPASS Pathways plc 1Q 2026: Revenue $91.2M, EPS ($0.3) — 10-Q Summary](https://longbridge.com/en/news/286244200.md)
*2026-05-13T10:41:00.000Z*
> COMPASS Pathways plc reported a significant revenue increase to $91.2M in Q1 2026, compared to a loss of $17.98M in the